SCA
GILD icon

Salient Capital Advisors’s Gilead Sciences GILD Stock Holding History

Salient Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-70,781
Closed -$5.01M – 106
2017
Q2 		$5.01M Buy
70,781
+3,456
+5% +$230K 0.1% 71
2017
Q1 		$4.57M Buy
67,325
+23,955
+55% +$1.68M 0.08% 75
2016
Q4 		$3.11M Buy
43,370
+3,507
+9% +$261K 0.06% 86
2016
Q3 		$3.15M Buy
39,863
+2,152
+6% +$175K 0.06% 82
2016
Q2 		$3.15M Buy
37,711
+4,220
+13% +$375K 0.07% 85
2016
Q1 		$3.08M Buy
+33,491
New +$3.02M 0.09% 82

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Salient Capital Advisors's GILD Position: Q3 2017 in Review

Salient Capital Advisors sold out of Gilead Sciences (GILD) in Q3 2017, closing a stake of 70,781 shares — an estimated $5.01M sold.

Salient Capital Advisors first reported a position in GILD in Q1 2016 and held it in 6 quarters. The position peaked at $5.01M in Q2 2017. 1,503 funds tracked by Wall St. Rank hold GILD as of Q3 2017.

  • Salient Capital Advisors reported no remaining Gilead Sciences position as of Q3 2017 after selling out during the quarter.
  • Salient Capital Advisors sold 70,781 Gilead Sciences shares in Q3 2017, an estimated $5.01M.
  • Salient Capital Advisors first reported a position in Gilead Sciences in Q1 2016 and held it in 6 quarters.
  • Salient Capital Advisors's Gilead Sciences position peaked at $5.01M in Q2 2017.
  • 1,503 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2017.

Based on Salient Capital Advisors's 13F filing for Q3 2017, filed 6 Nov 2017.